Additionally, single nucleotide polymorphisms in DPP-4 have been associated with responsiveness to drugs that target DPP-4, and with the risk of developing certain health conditions, including heart failure, type 2 diabetes mellitus, and dyslipidemia.46–52. Here, DPP4 is linked to metabolic syndrome.